Sciomics is a spin-off from the German Cancer institute, founded in April 2013, operating in the preclinical testing market with a focus on providing biomarker discovery services based on a unique antibody microarray platform. The range of services offered is broad, ranging from fixed content panels (scioCyto, scioCD, scioDiscover) or custom protein arrays (scioSpot) to the measurement of the phosphorylation or ubiquitinylation status of more than 1,000 proteins by a parallel analysis (scioPhospho and scioUbi). Sciomics has furthermore extensive experience in proteomic data analysis and has developed its own analysis routines as well as Machine Learning algorithms.
Dr Christoph Schröder
Dr. Christoph Schröder is the founder and CEO of Sciomics GmbH. He studied molecular biotechnology at the University of Bielefeld. As a PhD student and researcher, he spent a decade at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) developing antibody microarrays into a robust platform for highly parallel protein analyses. On this basis, he founded Sciomics GmbH together with Dr. Jörg Hoheisel in the spring of 2013 and has been managing director since then.
Mr Klein is a data scientist at Sciomics GmbH. An aspiring data scientist with a background from biotechnology/bioinformatics, his main interests lie in machine learning and big data, and include data analysis, and establishing analysis protocols for the scioPhospho profiling service at Sciomics.